Device-measured physical activity, sedentary time, and sleep in patients with arrhythmogenic cardiomyopathy: descriptive values and stability over 30 measurement days

David Ruiz-González[1,2], Jairo Hidalgo-Migueles[3], Javier Ramos-Maqueda[4], José Antonio Vargas-Hitos[5], Juan Jiménez-Jáimez[6], Alberto Soriano-Maldonado[1,2]

[1]Department of Education, Faculty of Education Sciences, University of Almería, Almería, Spain

[2]SPORT Research Group (CTS 1024), CERNEP Research Center, University of Almería, Almería, Spain

[3]Department of Physical and Sports Education, Faculty of Sport Sciences, University of Granada, Granada, Spain

[4]Cardiology Department, Lozano Blesa Clinical University Hospital, Zaragoza, Spain

[5]Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain.

[6]Cardiology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain

Corresponding author:

Jairo Hidalgo-Migueles: Department of Physical and Sports Education, Faculty of Sport Sciences, University of Granada, Granada, Spain. E-mail: jairo.hidalgo.migueles@ki.se

ABSTRACT

INTRODUCTION: Observational studies have consistently shown that exercise triggers and accelerate disease progression in patients with arrhythmogenic cardiomyopathy (AC), and sports participation is generally restricted. Therefore, individuals with AC may be susceptible to engage in low physical activity levels. This study aimed to objectively describe the patterns of physical activity (PA), sedentary time (SED), and sleep in patients with AC and to examine the reproducibility of accelerometer-derived measures over four consecutive weeks.

METHODS: A total of 71 (49.6 [SD=17.5] years) patients with AC wore a wrist-worn Axivity AX3 accelerometer for 30 consecutive days, and the raw signal was processed using the R-package GGIR. The participants were classified as meeting the 2020 World Health Organization guidelines using previously proposed thresholds for wrist accelerometers. The reproducibility of each metric was determined based on Intraclass Correlation Coefficients (ICCs; 95% CI) that were calculated using linear-mixed models adjusted for age, BMI, and season.

RESULTS: In total, 59.2% of participants did not meet the physical activity guidelines. AC patients spent 71.1% of awake time in SED and only 2.5% of awake time in moderate-to-vigorous physical activity (MVPA). No significant differences were found in physical activity related variables between sex and age groups. However, patients $\geq$50 years (n= 33) spent longer periods of sedentary time in comparison to those <50 years (mean difference 38.9 min/d, 95% CI 5.8 to 72.2, p = <0.05), and participants with obesity (BMI $\geq$30 kg/m^2, n= 10) accumulated longer periods of SED (mean difference 66.6 min/d, 95% CI 5.2 to 128.1, p = <0.05), and less MVPA (mean difference 22.8 min/d, 95% CI 0.7 to 44.9, p = <0.05) than those without obesity. The ICCs ranged from 0.77 for MVPA (95%

CI=0.72, 0.80) to 0.92 for light-intensity physical activity (95% CI=0.91, 0.93) using a 7-day assessment period, however, stability improved for assessment periods of 14 days.

CONCLUSION: Nearly 60% of the patients with AC did not meet the WHO 2020 physical activity guidelines. Accelerometer-based classifications of activity are moderately stable over time, indicating that a 7-day assessment period and to a greater extent a 14-day period provides a reproducible measure of physical activity, sedentary time and sleep.

INTRODUCTION

Arrhythmogenic cardiomyopathy (AC) may lead to ventricular arrhythmias and sudden cardiac death (1). The AC estimated prevalence ranges from 1:1000 to 1:5000, and 0.08% to 3.6% of the patients die annually (2). AC is a genetic disease of the cardiac muscle characterized by loss of cardiomyocytes and their replacement by fibrous or fibrofatty tissue. Dysfunctional desmosomes play a key role in the pathogenesis of AC (3), resulting in a progressive myocyte death and reduced wall stress tolerance. This leads to an early cardiac remodeling of the right ventricle (RV) with potential involvement of the left ventricle (LV) (4). AC usually onsets in the adulthood, with a median age at diagnosis of 31 years and a greater prevalence in males (5-7).

The available evidence indicates that decedents with a diagnosis of AC are more likely to have died at rest or during sleep compared to physical exertion (8). Notwithstanding, physical activity of vigorous intensity has been identified as a modulatory factor promoting disease progression (9–11). In fact, the European Society of Cardiology guidelines recommend that individuals with AC must avoid participation in activities of vigorous intensity because they have been related with accelerated disease progression, greater risk of sudden cardiac arrest and death (12,13). Nevertheless, recent World Health Organization (WHO) recommendations for adults (14) suggest the importance of not totally depriving individuals with chronic conditions from the many benefits of physical activity (PA), and safely participating in low to moderate intensity activities (15-18). Despite the contraindication to engage in vigorous PA, it is of wide clinical relevance to evaluate the extent to which light or moderate intensity PA might be related to the chronic benefits proposed by the ECS guidelines in AC patients. Moreover, parameters such as sedentary time (SED) and sleep have been poorly studied in this population and their influence on the clinical course of AC could be significant.

The activity patterns of people living with AC have only been described using self-reported measures (19-23). Activity monitors (e.g., accelerometers) might provide estimates of PA, SED, and sleep overcoming some of the bias that affect self-reported data (e.g., social desirability or recall bias) (24-28). Although the standard data collection protocols last seven days, the week-to-week stability of the measure has been questioned in the general population (29). Assessing the week-to-week stability of sleep, SED, and PA is of clinical interest to better characterize the variability of the behaviors in AC patients. The aims of this study were (a) to provide a detailed description of PA intensity parameters (light physical activity (LPA) and moderate-to-vigorous physical activity (MVPA)), SED, and sleep in a sample of Spanish adults with AC; (b) to quantify the week-to-week stability of the estimated outcomes (i.e., physical activity intensities, SED, and sleep).

METHODS

Study design and participants

We performed an observational study involving a total of 71 patients with Arrhythmogenic Cardiomyopathy (AC) from referral Inherited cardiovascular diseases Units of two tertiary hospitalary centers from Granada and Málaga. Patients were recruited from the clinical cohorts of two units specialized in the care of familial heart disease, the Virgen de las Nieves University Hospital (Granada, Spain) and the Virgen de la Victoria University Hospital (Malaga, Spain). Patients included were required to be diagnosed with AC as determined by the revised 2010 Task Force Diagnostic Criteria (30) or patients with a causative mutation for arrhythmogenic cardiomyopathy without the requirement to fulfil the criteria established by the 2010 task force. Additional inclusion criteria for the present study were the presence of an unequivocal diagnosis of left-dominant arrhythmogenic cardiomyopathy according to Padua Criteria (31).

The Research Ethics Committee of Granada approved the study protocol, and the research was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants.

Clinical Data Acquisition

Sociodemographic characteristics, medical history and device-measured PA, SED, and sleep were included. Participants were instructed to wear an accelerometer for 30 complete days (AX3, Axivity Ltd., Newcastle, UK). During this same period, arrhythmia measurement was performed by Nuubo textile holter®, a three-channel ECG recording system with cardiac event detection algorithms (32). Moreover, all patients were genetically characterized using large AC NGS panels in probands and Sanger sequencing cascade screening in relatives, and information regarding previous serious arrhythmic events such as cardiac arrest, sustained ventricular arrhythmias or appropriate therapy of the ICD was collected.

Accelerometer and data collection

To measure PA and sleep parameters patients wore a triaxial accelerometer (Axivity AX3©, Axivity Ltd, United Kingdom). The AX3 has been validated and used for measuring PA in a previous large-scale cohort study (33). Patients were instructed to wear the accelerometer on the non-dominant wrist 24 hours per day, for 30 consecutive days, and were instructed by the research team how to refit the accelerometer should they remove it for any reason. A valid measurement day was considered when participants wore the accelerometer for at least 16 hours per day. For a valid measurement week, participants must have recorded at least four valid days.

The accelerometer was set at a sampling frequency of 25 Hz, which is enough to capture most of the daily life accelerations related to physical movement and provides a close

measurement to the standard 100 Hz used in other studies (34). This decision was made to ensure the battery life and storage capacity of the device for the 30 days of data collection. Raw accelerometry data were downloaded as ".cwa" files and were processed with the R software using the GGIR package (v. 2.5-0, https://cran.r-project.org/web/packages/GGIR/) (35). In brief, the GGIR pipeline auto-calibrates the raw accelerations to the local gravity and aggregates them over to 5s epochs after removing the gravitational acceleration (36,37). Non-wear time is detected using 15-minute blocks with a 60-minute sliding window when the standard deviation of two out of the three axes was lower than 13 mg or the value range in two of the three axes was lower than 50 mg (38).

Sedentary time ($<$40 mg), and physical activity of light (LPA, 40-100 mg) and moderate-to-vigorous intensity (MVPA, $\geq$100 mg) were classified based on previously-validated acceleration thresholds (39,40). Additionally, sedentary bout lasting more than 30 consecutive minutes were identified with a tolerance of 10% of the bout time with accelerations $>$40 mg. Sleep-related outcomes were calculated using an automated algorithm based on the variability of the arm posture (41,42). Total sleep duration (minutes classified as asleep within the sleep period time (or time in bed)), time in bed, and sleep efficiency (the proportion of time spent sleeping from onset to termination: (sleep duration–wake after sleep onset (WASO)) / time in bed). Sleep efficiency ranges from 0 to 100, where a score of 100 indicates that the individual did not wake up between sleep onset and termination.

Matching Procedure

For descriptive analysis of metrics related to sleep, SED and PA, participants were block-matched on sex and age ($<$50 years, $\geq$50 years) that were self-reported. Height and weight were measured, and BMI was calculated as weight (kg) divided by squared height (m^2).

Overweight and obesity were defined as BMI 25-29.9 and $\geq$30 kg/m^2, respectively, and three age groups were created (normal weight, overweight and obesity). In addition, differences in PA levels were analyzed for disease-related variables that might affect the amount of PA. These variables divided participants according to cardioverter defibrillator implantation (ICD) and the presence of desmosomal protein gene mutations.

Statistical analysis

Due to the non-normal distribution of most PA variables (assessed with the Kolmogorov Smirnov test), descriptive characteristics are presented using medians and interquartile ranges (IQR). Differences among groups stratified by socio-demographic and clinical characteristics in normally distributed numerical variables were tested using one-way analysis of variance (ANOVA), and by Mann-Whitney U test in case of deviation from normal distribution. For each activity metric, the weekly average was calculated and Friedman test with Bonferroni's adjustment were used to estimate whether the accelerometer metric changed over time. To assess the stability over the four weeks for all participants combined, the intraclass correlation coefficients (ICC) was used by dividing the between-person variance by the sum of the between-person and within-person variances. Between-person and within-period variances were estimated using random effects models that included average weekly value for each metric at each of the four weeks. ICCs are presented with and without adjustment for age, BMI, and season of the year. Ninety-five percent confidence intervals were calculated for the ICCs based on a two-way mixed effects model, using single measures, and absolute agreement. Further, reliability associations were classified based on the 95% confidence intervals of the ICC estimate as poor (0–0.49), moderate (0.50–0.74), good (0.75–0.89), or excellent (0.90–1.00) [43]. To assess the utility of a single 7-day measurement to correctly classify longer term activity parameter into tertile categories, we compared tertiles of physical activity

(as measured by the first week) to tertiles defined from the average of the remaining weeks. All statistical analyses were performed using SPSS version 25.0 (SPSS Inc., Chicago, IL, USA) and Stata (version 16.1.0; Stata Corporation, College Station, TX, United States). Values of p < 0.05 were considered statistically significant.

RESULTS

Characteristics of the study population are presented in **Table 1**. Of the overall study participants (n = 71), median age was 51.5 (IQR 24.0) years (range from 16 to 78 years) and 36/67 (50.7%) were women. In the total AC participants, 52.1% had an ICD in situ and 28.8% were symptomatic based on NYHA class (>1). A total of 34.8% had documented ventricular tachycardia or ventricular fibrillation and 23.1% a history of syncope.

Physical activity, sedentary time, and sleep

Based on the World Health Organization physical activity recommendations for adults living with chronic conditions (14), 59.2% of participants did not meet with the recommendations of 150 min/week of MVPA based on accelerometer data.

Participants had a median (IQR) of 21.0 (1.0) valid weekdays and 8.0 (0) valid weekend days, and non-wear time during the awake time was 0.9% (3.1). Accelerometer data were obtained from 71 AC individuals, of whom 65 had data from four consecutive weeks and satisfied requirements for a minimum of 2/3 day wear time on a minimum of 4 days a week. Overall, participants spent 71.1% of daily awake time in SED and only 2.4% in MVPA.

There were small differences in PA and SED by sex and age (Table 2). Participants ≥50 years spent a greater amount of time is accumulated in periods of ≥30 minutes of SED (94.6 min/d [IQR 102.9]) in comparison to those <50 years (50.4 min/d [IQR 49.1]).

Similarly, for BMI groups, obese participants have twice as much time in periods of at least 30 minutes of SED as normal weight participants (95.3 min/d [IQR 160.7] vs. 45.8 min/d [IQR 43.7]), in contrast to the time spent in MVPA, with lower levels compared to the normal weight group (8.3 min/d [IQR 16.3] vs. 20.8 min/d [IQR 22.7]). The sleep efficiency was 90.0%, with a mean of 96.2 min/d of WASO. There were no marked differences in these sleep patterns according to age, sex, and BMI groups. Nevertheless, when considering clinical characteristics, differences in sleep-related variables did emerge. Participants with implantable cardioverter-defibrillator (ICD) showed a reduction in sleep time (6.2 h/d [IQR 0.8] vs. 6.6 h/d [IQR 1.4]) as well as efficiency (88.3 % [IQR 4.0] vs. 90.8 % [IQR 4.8]). Similarly, patients with desmosomal mutations showed a reduction in both sleep time and efficiency.

Stability of Accelerometer-Assessed PA and SED

The unadjusted ICCs (95% CIs) ranged from 0.60 (95% CI=0.49, 0.71) for time in bed to 0.93 (95% CI=0.90, 0.95) for LPA when a 7-day assessment period was considered, however, 14-day administration of accelerometers resulted in better ICCs and ranged from 0.77 (95% CI=0.65, 0.85) for time in bed to 0.95 (95% CI=0.92, 0.97) for LPA (Table 3). ICC values were slightly higher for most variables with adjustment for age, BMI, and season (Table 4). In the stratified analysis, the ICCs were different for all activity metrics between younger and older (Table 4). Younger group (<50 years) showed higher ICCs for SED and LPA metrics. However, for MVPA, the ICCs were significantly higher for older group (0.85 and 0.75, respectively), which may be related to their lower participation in these PA intensities. Similarly, when stratified by BMI, the group composed by obese individuals showed a higher ICC for MVPA, compared with normal weight group (0.94 and 0.65, respectively). In addition, ICCs were generally higher for the winter season. As there were some subjects who had no accelerometer data for all four

weeks, a sensitivity analysis was conducted to examine the impact of the different sample sizes at weeks two, three and four on the ICCs (Table 5).

Table 6 shows the changes in the ICCs when stability was analyzed for 7 and 14 day assessment periods, removing the first day of measurement in order to avoid possible measurement reactivity. The exclusion of the first day of measurement did not produce significant changes and the ICCs remained relatively stable.

To compare the consistency of activity classification, participants were cross classified by tertile distributions at week one compared to weeks two, three and four. For total SED time, there were 55/65 participants (84.6%) who were classified in the same tertile at the different timepoints. For the total amount of LPA and MVPA, 83.1% and 75.4% were classified in the same tertile at different timepoints (Table 7).

DISCUSSION

The main findings of the present study indicate that individuals with AC spend >70% of their awake time in sedentary behaviors, nearly 60% do not meet the minimum amount of MVPA recommended by the WHO for people with chronic conditions, and 80% of participants did not meet the sleep guidelines for adults. This highlights that these behaviors might represent potential risk factors that compromise the cardiovascular health of patients with AC in the mid- and long-term. Another important finding indicate that the stability of the behavioral metrics assessed across different weeks ranged from moderate to excellent, and it actually improved for assessment periods of 14 (instead of 7) days.

Individuals diagnosed with AC are recommended to avoid from participating in activities of vigorous intensity and competitive sports because they have been related with accelerated disease progression, greater risk of sudden cardiac arrest and death (12,13,19,

44). Studies, such as one conducted in Veneto, a region of Italy, confirm the deleterious effect of competitive sports in inherited cardiomyopathies (45). However, the extent to which these recommendations result in lifestyle changes that end up in low physical activity levels and large period of sedentary time in AC patients is poorly understood, and it is significant as PA is robustly associated with a decrease in cardiovascular mortality as well as the risk of developing cardiovascular disease (44,46). This study provides a detailed description of PA, SED and sleep, over the full 24-hour cycle from raw accelerometer data in a sample of well-characterized patients with AC from Spain. Overall, 71.1% of the participants' daily awake time was classified as SED and 59.2% of them did not meet a minimum of 150 min/week of MVPA as recommended by the WHO physical activity guidelines.

The use of accelerometers in AC patients has been conducted for first time in this study. Previous research has relied on self-reported assessments of SED and PA (19-23). However, self-reported tools may be subject to response bias, such as social desirability bias (i.e. overestimation of PA which may be greater in men and in people with lower education), or recall bias that leads to inaccurate memories of PA (19-23). Accelerometers allows monitoring the full 24-h activity cycle and provides complete information on the activity patterns, including the sleep period (47). Our study confirms that AC patients restrict their activity and spent most of the day in SED with a median of 12.2 hours per day. Further, most SED was accumulated in bouts lasting <30min, as the median for SED bouts lasting ≥30 min was 61.3 minutes per day. Participants spent less time in MVPA (median of 17.9 min/day) than in LPA (median of 3.4 hours/day), which confirms that MVPA is greatly reduced in this population, findings that are consistent with lifestyle changes in individuals with other cardiac disorders, such as hypertrophic cardiomyopathy and Peripheral Artery Disease (48-50). No marked differences were

generally observed in activity patterns by socio-demographic factors and BMI; however, the group of participants aged 50 years and older accumulated a higher amount of SED in periods of at least 30 minutes (SED30min), and there was a trend to reduce MVPA, with fewer participants reaching the minimum recommendations for PA. Similarly, in the groups stratified by BMI, the group of obese people showed the same tendencies, and this is not surprising as studies in healthy adults have shown a similar trend, where MVPA declined in later life and with increasing BMI (52-53). Related to sleep parameters, the median sleep time was 6.4 h/d with 90% of sleep efficacy. Sleep data obtained with the accelerometer were homogeneous between groups, but when considering different clinical characteristics, a decrease in both total sleep time and sleep efficiency was observed in the implantable cardioverter defibrillator (ICD) and desmosomal mutations groups. The available evidence also indicates that sleep disturbances are highly prevalent in patients with ICD (54).

In the present study, we also analyzed the stability of accelerometer-assessed PA and SED over 4 consecutive weeks. In general, it is believed that adequate stability is achieved if a PA administration protocol includes a minimum of four consecutive days (55,56), therefore, the most common administration approach uses seven consecutive days (57). However, for epidemiological studies, researchers are often interested in describing habitual physical activity over longer periods of time as there may be variability from week to week for a variety of reasons. The ICCs obtained when analyzing the stability of the sleep, SED and PA metrics over four consecutive weeks and using 7-day assessment period were moderate to excellent and were similar with or without adjustment for age, BMI, and season. However, a 14-day assessment period improved stability for sleep, SED and PA metrics, turning moderate stability into good stability. Therefore, a 14-day assessment period in patients with AC would be sufficient to achieve adequate stability,

which would provide further accurate information about activity patterns in people with AC. In addition, when stratifying by socio-demographic characteristics, higher ICCs, mainly related to MVPA, are observed for older and heavier weight groups. These differences have also been reported in studies analyzing physical activity in healthy adults, which is related to their lower participation in physical activity and more uniform and sedentary lifestyles (58,29).

This study confirms previous findings based on self-reports of reduced levels of PA, mainly MVPA, and a significant prevalence of sedentary behaviors in patients with arrhythmogenic cardiomyopathies, findings that are in line with lifestyle changes in people with other cardiac conditions and related to recommendations for restricting vigorous-intensity activity. Despite the current evidence suggesting that competitive sports or high intensity exercise might accelerate disease progression (9-13), these results are clinically relevant because they underlie that patients with AC are widely inactive and sedentary. This clearly underlines that many AC patients could obtain important health-related benefits from restricting sedentary time and being more physically active, even if these activities are of light or moderate intensities. The extent to which device-measured physical activity, sedentary time and sleep are related the presence of classical cardiovascular risk factors or ischemic cardiovascular disease in AC is a relevant matter for future research.

REFERENCES

1. Hutchinson MD. Arrhythmogenic right ventricular cardiomyopathy. Card Electrophysiol Clin Case Rev. 2020;493–7.

2. Bazoukis G, Letsas KP, Thomopoulos C, Tse G, Korantzopoulos P, Naka KK, et al. Predictors of Adverse Outcomes in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy: A Meta-Analysis of Observational Studies. Cardiol Rev. 2019;27(4):189–97.

3. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki

A, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. Eur Heart J [Internet]. 2020 Apr 7 [cited 2021 Nov 22];41(14):1414–29. Available from: https://academic.oup.com/eurheartj/article/41/14/1414/5602183

4. Hoorntje ET, Te Rijdt WP, James CA, Pilichou K, Basso C, Judge DP, et al. Arrhythmogenic cardiomyopathy: Pathology, genetics, and concepts in pathogenesis. Cardiovasc Res. 2017;113(12):1521–31.

5. Groeneweg JA, Bhonsale A, James CA, Te Riele AS, Dooijes D, Tichnell C, et al. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015;8(3):437–46.

6. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, H Jongbloed JD, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36:847–55.

7. Van der Voorn SM, te Riele ASJM, Basso C, Calkins H, Remme CA, van Veen TAB. Arrhythmogenic cardiomyopathy: Pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy. Cardiovasc Res. 2020;116(9):1571–84.

8. Miles C, Finocchiaro G, Papadakis M, Gray B, Westaby J, Ensam B, et al. Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. Circulation. 2019;139(15):1786–97.

9. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right Ventricular Cardiomyopathy and Sudden Death in Young People. http://dx.doi.org/101056/NEJM198801213180301 [Internet]. 2010 Jan 14 [cited 2021 Nov 22];318(3):129–33. Available from: https://www.nejm.org/doi/10.1056/NEJM198801213180301

10. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol [Internet]. 2017 Jun 15 [cited 2021 Nov 22];237:67–70. Available from: http://www.internationaljournalofcardiology.com/article/S0167527317307131/fulltext

11. Sawant AC, Bhonsale A, te Riele ASJM, Tichnell C, Murray B, Russell SD, et al. Exercise has a disproportionate role in the pathogenesis of arrhythmogenic right ventricular dysplasia/cardiomyopathy in patients without desmosomal mutations. J Am Heart Assoc [Internet]. 2014 [cited 2021 Nov 22];3(6). Available from: https://pubmed.ncbi.nlm.nih.gov/25516436/

12. Ruwald AC, Marcus F, Estes NAM, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J [Internet]. 2015 Jul 14 [cited 2021 Nov 22];36(27):1735–43. Available from: https://pubmed.ncbi.nlm.nih.gov/25896080/

13. Ruiz Salas A, Barrera Cordero A, Navarro-Arce I, Jiménez Navarro M, García Pinilla JM, Cabrera Bueno F, et al. Impact of dynamic physical exercise on high-

risk definite arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Electrophysiol [Internet]. 2018 Nov 1 [cited 2021 Nov 22];29(11):1523–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jce.13704

14. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med [Internet]. 2020 Dec 1 [cited 2022 Apr 7];54(24):1451–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33239350/

15. Maron BJ, Chaitman BR, Ackerman MJ, De Luna AB, Corrado D, Crosson JE, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation [Internet]. 2004 Jun 8 [cited 2021 Nov 22];109(22):2807–16. Available from: https://pubmed.ncbi.nlm.nih.gov/15184297/

16. Pelliccia A, Solberg EE, Papadakis M, Adami PE, Biffi A, Caselli S, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). [cited 2021 Nov 22]; Available from: https://academic.oup.com/eurheartj/article/40/1/19/5248228

17. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96.

18. Reid H, Ridout AJ, Tomaz SA, Kelly P, Jones N. Benefits outweigh the risks: a consensus statement on the risks of physical activity for people living with long-term conditions. Br J Sport Med [Internet]. 2022 [cited 2022 May 13];56:427–38. Available from: http://bjsm.bmj.com/

19. Pelliccia A, Corrado D, Bjã¸rnstad HH, Panhuyzen-Goedkoop N, Urhausen A, Carre F, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil [Internet]. 2006 Dec 1 [cited 2022 Apr 7];13(6):876–85. Available from: https://academic.oup.com/eurjpc/article/13/6/876/5932819

20. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol [Internet]. 2013 Oct 1 [cited 2022 Apr 7];62(14):1290–7. Available from: https://pubmed.ncbi.nlm.nih.gov/23871885/

21. Lie ØH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T, et al. Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy. JACC Clin Electrophysiol. 2018;4(6):744–53.

22. Ruwald AC, Marcus F, Estes NAM, Link M, McNitt S, Polonsky B, et al. Association of competitive and recreational sport participation with cardiac events in patients with arrhythmogenic right ventricular cardiomyopathy: results from the North American multidisciplinary study of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J [Internet]. 2015 Jul 14 [cited 2021 Nov 22];36(27):1735–43. Available from: https://pubmed.ncbi.nlm.nih.gov/25896080/

23. Ruiz Salas A, Barrera Cordero A, Navarro-Arce I, Jiménez Navarro M, García Pinilla JM, Cabrera Bueno F, et al. Impact of dynamic physical exercise on high-risk definite arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Electrophysiol [Internet]. 2018 Nov 1 [cited 2021 Nov 22];29(11):1523–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/jce.13704

24. Shiraishi Y, Niimi N, Goda A, Takei M, Kimura T, Kohno T, et al. Assessment of physical activity using waist-worn accelerometers in hospitalized heart failure patients and its relationship with kansas city cardiomyopathy questionnaire. J Clin Med. 2021;10(18).

25. Klompstra L, Kyriakou M, Lambrinou E, Piepoli MF, Coats AJS, Cohen-Solal A, et al. Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail [Internet]. 2021 Jan 1 [cited 2021 Nov 22];23(1):83–91. Available from: https://pubmed.ncbi.nlm.nih.gov/33111464/

26. Berlin JE, Storti KL, Brach JS. Using Activity Monitors to Measure Physical Activity in Free-Living Conditions. Phys Ther [Internet]. 2006 Aug 1 [cited 2021 Nov 22];86(8):1137–45. Available from: https://academic.oup.com/ptj/article/86/8/1137/2857471

27. Fjeldsoe BS, Winkler EAH, Marshall AL, Eakin EG, Reeves MM. Active adults recall their physical activity differently to less active adults: test-retest reliability and validity of a physical activity survey. Health Promot J Austr [Internet]. 2013 Apr [cited 2021 Nov 22];24(1):26–31. Available from: https://pubmed.ncbi.nlm.nih.gov/23575586/

28. Dyrstad SM, Hansen BH, Holme IM, Anderssen SA. Comparison of self-reported versus accelerometer-measured physical activity. Med Sci Sports Exerc [Internet]. 2014 Jan [cited 2021 Nov 22];46(1):99–106. Available from: https://pubmed.ncbi.nlm.nih.gov/23793232/

29. Keadle SK, Shiroma EJ, Kamada M, Matthews CE, Harris TB, Lee IM. Reproducibility of Accelerometer-Assessed Physical Activity and Sedentary Time. Am J Prev Med [Internet]. 2017 Apr 1 [cited 2022 Apr 9];52(4):541–8. Available from: http://www.ajpmonline.org/article/S0749379716305888/fulltext

30. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J [Internet]. 2010 [cited 2021 Dec 10];31(7):806–14. Available from: https://pubmed.ncbi.nlm.nih.gov/20172912/

31. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M De, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol [Internet]. 2020 Nov 15 [cited 2022 May 13];319:106–14. Available from: http://www.internationaljournalofcardiology.com/article/S0167527320332939/fulltext

32. Perez De Isla L, Lennie V, Quezada M, Guinea J, Arce C, Abad P, et al. New generation dynamic, wireless and remote cardiac monitorization platform: a feasibility study. Int J Cardiol [Internet]. 2011 Nov 17 [cited 2021 Dec

10];153(1):83–5. Available from: https://pubmed.ncbi.nlm.nih.gov/21925751/

33. Clarke CL, Taylor J, Crighton LJ, Goodbrand JA, McMurdo MET, Witham MD. Validation of the AX3 triaxial accelerometer in older functionally impaired people. Aging Clin Exp Res [Internet]. 2017 Jun 1 [cited 2021 Dec 10];29(3):451–7. Available from: https://pubmed.ncbi.nlm.nih.gov/27435918/

34. Small S, Khalid S, Dhiman P, Chan S, Jackson D, Doherty A, et al. Impact of Reduced Sampling Rate on Accelerometer-Based Physical Activity Monitoring and Machine Learning Activity Classification. J Meas Phys Behav [Internet]. 2021 Sep 30 [cited 2022 Apr 6];4(4):298–310. Available from: https://journals.humankinetics.com/view/journals/jmpb/4/4/article-p298.xml

35. Migueles JH, Rowlands A V., Huber F, Sabia S, Hees VT van. GGIR: A Research Community–Driven Open Source R Package for Generating Physical Activity and Sleep Outcomes From Multi-Day Raw Accelerometer Data. J Meas Phys Behav [Internet]. 2019 Sep 1 [cited 2022 Apr 6];2(3):188–96. Available from: https://journals.humankinetics.com/view/journals/jmpb/2/3/article-p188.xml

36. Van Hees VT, Fang Z, Langford J, Assah F, Mohammad A, Da Silva ICM, et al. Autocalibration of accelerometer data for free-living physical activity assessment using local gravity and temperature: an evaluation on four continents. J Appl Physiol [Internet]. 2014 Oct 1 [cited 2022 Apr 6];117(7):738–44. Available from: https://pubmed.ncbi.nlm.nih.gov/25103964/

37. van Hees VT, Gorzelniak L, Dean León EC, Eder M, Pias M, Taherian S, et al. Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity. PLoS One [Internet]. 2013 Apr 23 [cited 2022 May 13];8(4). Available from: https://pubmed.ncbi.nlm.nih.gov/23626718/

38. van Hees VT, Renström F, Wright A, Gradmark A, Catt M, Chen KY, et al. Estimation of daily energy expenditure in pregnant and non-pregnant women using a wrist-worn tri-axial accelerometer. PLoS One [Internet]. 2011 [cited 2022 Apr 6];6(7). Available from: https://pubmed.ncbi.nlm.nih.gov/21829556/

39. Hildebrand M, Van Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc [Internet]. 2014 [cited 2022 Apr 6];46(9):1816–24. Available from: https://pubmed.ncbi.nlm.nih.gov/24887173/

40. Hildebrand M, Hansen BH, van Hees VT, Ekelund U. Evaluation of raw acceleration sedentary thresholds in children and adults. Scand J Med Sci Sports [Internet]. 2017 Dec 1 [cited 2022 Apr 6];27(12):1814–23. Available from: https://pubmed.ncbi.nlm.nih.gov/27878845/

41. Van Hees VT, Sabia S, Anderson KN, Denton SJ, Oliver J, Catt M, et al. A Novel, Open Access Method to Assess Sleep Duration Using a Wrist-Worn Accelerometer. PLoS One [Internet]. 2015 Nov 1 [cited 2022 May 13];10(11). Available from: https://pubmed.ncbi.nlm.nih.gov/26569414/

42. van Hees VT, Sabia S, Jones SE, Wood AR, Anderson KN, Kivimäki M, et al. Estimating sleep parameters using an accelerometer without sleep diary. Sci Rep [Internet]. 2018 Dec 1 [cited 2022 May 13];8(1). Available from:

https://pubmed.ncbi.nlm.nih.gov/30154500/

43. Rosner, B. Fundamentals of biostatistics. 5th ed. Duxbury Press; Belmont, CA: 2005

44. Ramakrishnan R, Doherty A, Smith-Byrne K, Rahimi K, Bennett D, Woodward M, et al. Accelerometer measured physical activity and the incidence of cardiovascular disease: Evidence from the UK Biobank cohort study. PLOS Med [Internet]. 2021 Jan 12 [cited 2022 Apr 7];18(1):e1003487. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003487

45. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program. JAMA [Internet]. 2006 Oct 4 [cited 2022 May 13];296(13):1593–601. Available from: https://jamanetwork.com/journals/jama/fullarticle/203513

46. Nystoriak MA, Bhatnagar A. Cardiovascular Effects and Benefits of Exercise. Front Cardiovasc Med. 2018;5(September):1–11.

47. Rosenberger ME, Fulton JE, Buman MP, Troiano RP, Grandner MA, Buchner DM, et al. The 24-Hour Activity Cycle: A New Paradigm for Physical Activity. Med Sci Sports Exerc [Internet]. 2019 Mar 1 [cited 2022 Apr 9];51(3):454–64. Available from: https://journals.lww.com/acsm-msse/Fulltext/2019/03000/The_24_Hour_Activity_Cycle__A_New_Paradigm_fo r.9.aspx

48. Shiba S, Shiba A, Hatada A. Differences in Physical Activity between Patients with Peripheral Artery Disease and Healthy Subjects. J Aging Res. 2020

49. Sweeting J, Ingles J, Timperio A, Patterson J, Ball K, Semsarian C. Physical activity in hypertrophic cardiomyopathy: Prevalence of inactivity and perceived barriers. Open Hear. 2016;3(2):1–9.

50. Gerage AM, Correia M de A, de Oliveira PML, Palmeira AC, Domingues WJR, Zeratti AE, et al. Physical activity levels in peripheral artery disease patients. Arq Bras Cardiol. 2019;113(3):410–6.

51. Hansen BH, Holme I, Anderssen SA, Kolle E. Patterns of Objectively Measured Physical Activity in Normal Weight, Overweight, and Obese Individuals (20–85 Years): A Cross-Sectional Study. PLoS One [Internet]. 2013 Jan 7 [cited 2022 Apr 9];8(1):e53044. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053044

52. Tudor-Locke C, Brashear MM, Johnson WD, Katzmarzyk PT. Accelerometer profiles of physical activity and inactivity in normal weight, overweight, and obese U.S. men and women. Int J Behav Nutr Phys Act [Internet]. 2010 Aug 3 [cited 2022 Apr 9];7(1):1–11. Available from: https://ijbnpa.biomedcentral.com/articles/10.1186/1479-5868-7-60

53. Smith L, Gardner B, Fisher A, Hamer M. Patterns and correlates of physical activity behaviour over 10 years in older adults: prospective analyses from the English Longitudinal Study of Ageing. BMJ Open [Internet]. 2015 Apr 1 [cited 2022 Apr 9];5(4):e007423. Available from: https://bmjopen.bmj.com/content/5/4/e007423

54. Habibović M, Mudde L, Pedersen SS, Schoormans D, Widdershoven J, Denollet J. Sleep disturbance in patients with an implantable cardioverter defibrillator: Prevalence, predictors and impact on health status. Eur J Cardiovasc Nurs [Internet]. 2018 Jun 1 [cited 2022 Apr 9];17(5):390–8. Available from: https://academic.oup.com/eurjcn/article/17/5/390/5924968

55. Sasaki JE, Júnior JH, Meneguci J, Tribess S, Marocolo Júnior M, Stabelini Neto A, et al. Number of days required for reliably estimating physical activity and sedentary behaviour from accelerometer data in older adults. https://doi.org/101080/0264041420171403527 [Internet]. 2017 Jul 18 [cited 2022 Apr 7];36(14):1572–7. Available from: https://www.tandfonline.com/doi/abs/10.1080/02640414.2017.1403527

56. Hart TL, Swartz AM, Cashin SE, Strath SJ. How many days of monitoring predict physical activity and sedentary behaviour in older adults? Int J Behav Nutr Phys Act [Internet]. 2011 May 16 [cited 2022 Apr 7];8(1):1–7. Available from: https://ijbnpa.biomedcentral.com/articles/10.1186/1479-5868-8-62

57. Migueles JH, Cadenas-Sanchez C, Ekelund U, Delisle Nyström C, Mora-Gonzalez J, Löf M, et al. Accelerometer Data Collection and Processing Criteria to Assess Physical Activity and Other Outcomes: A Systematic Review and Practical Considerations. Sports Med [Internet]. 2017 Sep 1 [cited 2022 Apr 7];47(9):1821. Available from: /pmc/articles/PMC6231536/

58. Saint-Maurice PF, Sampson JN, Keadle SK, Willis EA, Troiano RP, Matthews CE. Reproducibility of Accelerometer and Posture-derived Measures of Physical Activity. Med Sci Sports Exerc [Internet]. 2020 Apr 1 [cited 2022 Apr 9];52(4):876–83. Available from: https://journals.lww.com/acsm-msse/Fulltext/2020/04000/Reproducibility_of_Accelerometer_and.13.aspx

Table 1. Baseline characteristics

Variable	n=71
Age, *mean (SD)*	49.6 (17.5)
Female (%)	36/67 (50,7%)
BMI	
Normal (BMI 18.5-25)	23/60 (32,4%)
Overweight (BMI 25-30)	27/60 (38.0%)
Obese (BMI>18.5)	10/60 (14,1%)
Genotype[a] (% positive)	57/66 (86,4%)
DSP	13/57
DSG2	5/57
PKP2	8/57
FLNC	14/57
TMEM43	5/57
LMNA	2/57
DES	9/57
Desmosomal mutation (%)	32/64 (45,1%)
Phenotype	
Right	8/66 (12,1%)
Left	30/66 (45,5%)
Biventricular	28/66 (42,4 %)
ICD implanted	37/65 (52,1 %)
Arrythmic risk[b] (% high)	22/65 (31.0 %)
Time since diagnosis (years), *mean (SD)*	7.02 (4.98)
VT/VF history	23/66 (34.8 %)
Syncope	15/65 (23.1 %)
Appropriate ICD therapy	13/66 (19.7 %)
LVEF (%), *mean (SD)*	50.39 (11.92)
NYHA (<1)	19/66 (28.8%)

BMI, body mass index; DES, Desmin; DSG2, Desmoglein-2; DSP, Desmoplakin; FLNC, Filamin C; ICD, implantable cardioverter defibrillator; LMNA, Lamin A/C; LVEF, Left Ventricular Ejection Fraction; NYHA, New York Heart Association functional classification; PKP2, Plakophilin-2; TMEM43, Transmembrane protein 43; VT/VF, ventricular tachycardia/ventricular fibrillation.

[a]High risk patients have a >10% per year risk of a major arrhythmic event, while intermediate-risk patient has 1-10% per year risk, and low-risk patient have a less than 1%per year risk for major arrhythmic events.

[b] Genotype positive status was defined as having at least one variant that was deemed pathogenic or presumed pathogenic.

Table 2: Time spent in sleep, sedentary behavior, light physical activity, and moderate-to-vigorous physical activity in the whole sample and stratified by sex and age.

	n	SLEEP			Sedentary		LPA	MVPA	Guidelines
		Time in bed (h/d)	Total sleep (h/d)	Efficiency (%)	SED_{Total} (h/d)	SED_{30min} (min/d)	Total (h/d)	Total (min/d)	Total[a]
All	71	7.14 (0.94)	6.36 (0.97)	90.10 (5.14)	12.16 (2.11)	61.30 (82.14)	3.41 (1.68)	17.94 (24.50)	29 (40.8%)
Men	36	7.09 (0.84)	6.26 (0.82)	88.66 (5.27)	12.38 (1.63)	65.61 (93.23)	3.39 (1.56)	18.84 (27.91)	17/28 (60.7%)
Women	29	7.14 (1.30)	6.36 (1.32)	90.18 (5.27)	11.85 (2.44)	57.73 (80.69)	3.73 (1.86)	17.87 (25.00)	11/28 (39.3%)
p		0.428	0.271	0.376	0.142	0.704	0.214	0.894	
<50	29	7.16 (1.18)	6.36 (0.75)	88.51 (6.32)	12.28 (3.67)	50.36 (49.14)	3.41 (2.04)	19.31 (24.70)	15/26 (57.7%)
≥50	33	7.13 (1.15)	6.28 (1.10)	90.25 (4.79)	12.14 (1.47)	94.59 (102.93)	3.47 (1.62)	13.51 (28.81)	11/26 (42.3%)
p		0.856	0.752	0.350	0.357	**0.002**	0.209	0.386	
Normal	23	7.14 (0.95)	6.52 (1.03)	90.39 (4.34)	11.72 (3.41)	45.75 (43.69)	3.69 (1.71)	20.77 (22.72)	11/24 (45.8%)
Overweight	27	7.13 (0.89)	6.27 (0.96)	88.54 (4.53)	12.29 (1.38)	84.13 (77.89)	3.43 (1.82)	15.43 (28.69)	11/24 (45.8%)
Obesity	10	7.05 (1.62)	6.30 (1.22)	90.20 (5.58)	12.07 (2.71)	95.27 (160.68)	3.45 (1.75)	8.33 (16.29)	2/24 (8.3%)
p		0.856	0.169	0.083	0.522	**0.025**	0.994	**0.077**	
N-ICD	26	7.26 (1.19)	6.64 (1.37)	90.81 (4.79)	11.74 (2.52)	59.51 (91.99)	3.10 (1.96)	18.82 (23.78)	8/25 (32.0%)
ICD	37	6.96 (0.97)	6.22 (0.75)	88.28 (4.01)	12.34 (1.82)	60.00 (88.26)	3.68 (1.54)	15.85 (27.59)	17/25 (68.0%)
p		0.126	**0.013**	**0.008**	0.094	0.239	0.476	0.359	
N-DM	30	7.22 (0.99)	6.49 (0.88)	90.50 (4.81)	12.38 (1.93)	54.60 (68.86)	3.39 (1.80)	20.51 (23.39)	16/27 (59.3%)
DM	32	6.98 (0.93)	6.14 (0.99)	87.93 (3.74)	11.91 (2.25)	83.18 (130.04)	3.70 (1.68)	11.96 (26.92)	11/27 (40.7%)
p		0.578	0.081	**0.032**	0.546	0.248	0.510	0.186	

Data are medians and interquartile ranges. P-values denote significance of non-parametric test for trend across categories (P < 0.05). Values are rounded. DM = Desmosomal mutation; ICD = Implantable cardioverter-defibrillator; LPA = light-intensity physical activity; MVPA = moderate-to-vigorous physical activity.

[a] Participants meeting physical activity guidelines (%) of 150 min or more moderate–vigorous physical activity per week.

Table 3: Descriptive Statistics and Intraclass Correlation Coefficient (ICC) for physical activity, sedentary time and sleep over 4 weeks.

	Week 1 (N=65)	Week 2 (N=65)	Week 3 (N=65)	Week 4 (N=65)			
Variable	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	P	ICC (95% CI)[a]	ICC (95% CI)[b]
Time in bed (h/d)	7.20 (1.17)	7.14 (1.35)	7.28 (1.29)	7.16 (1.24)	0.69	0.60 (0.49, 0.71)	0.77 (0.65, 0.85)
Total sleep (h/d)	6.44 (1.11)	6.28 (1.26)	6.48 (1.16)	6.47 (1.15)	0.84	0.66 (0.55, 0.75)	0.78 (0.66, 0.86)
Sleep efficiency (%)	90.13 (6.01)	90.16 (5.40)	89.72 (5.82)	89.87 (5.00)	0.71	0.57 (0.45, 0.68)	0.66 (0.50, 0.78)
SED (h/d)	12.31 (2.26)	12.21 (2.35)	12.25 (2.47)	12.18 (2.54)	0.74	0.89 (0.84, 0.92)	0.94 (0.91, 0.97)
SED30min (min/d)	70.70 (86.23)	74.27 (91.36)	59.14 (101.51)	60.33 (95.86)	0.14	0.77 (0.68, 0.84)	0.86 (0.78, 0.91)
LPA (min/d)	205.39 (114.32)	199.63 (117.55)	208.40 (121.46)	201.23 (107.57)	0.02	0.93 (0.90, 0.95)	0.95 (0.92, 0.97)
MVPA (min/d)	16.37 (23.86)	17.06 (21.34)	15.07 (26.04)	16.77 (23.76)	0.52	0.80 (0.72, 0.86)	0.88 (0.81, 0.92)

P<0.05 indicates statistical significance (p-values are from repeated measures linear mixed models).

IQR = Interquartile range; LPA = light-intensity physical activity; MVPA = moderate-to-vigorous physical activity; SED = Sedentary time

Notes: ICCs are unadjusted.

[a] ICCs using a single 7-day assessment period.

[b] ICCs using a 14-day assessment period.

Table 4: Intraclass Correlation Coefficient (ICC) for Activity Metrics stratified by Age, BMI and season over 4 weeks.

Variables	n	Time in bed (h/d)	Total Sleep (h/d)	SED (h/d)	SED$_{30min}$ (min/d)	LPA (min/d)	MVPA (min/d)
Overall (adjusted)[a]	65	0.67 (0.61, 0.72)	0.72 (0.66, 0.76)	0.90 (0.88, 0.92)	0.81 (0.77, 0.84)	0.92 (0.91, 0.93)	0.77 (0.72, 0.80)
Younger	27	0.61 (0.43, 0.77)	0.60 (0.42, 0.77)	0.94 (0.89, 0.97)	0.87 (0.79, 0.93)	0.93 (0.88, 0.97)	0.75 (0.62, 0.86)
Older	30	0.63 (0.46, 0.78)	0.72 (0.58, 0.84)	0.82 (0.71, 0.90)	0.73 (0.59, 0.84)	0.90 (0.86, 0.95)	0.85 (0.76, 0.92)
Normal weight	19	0.61 (0.40, 0.80)	0.63 (0.43, 0.81)	0.92 (0.85, 0.96)	0.77 (0.61, 0.89)	0.95 (0.91, 0.98)	0.65 (0.45, 0.83)
Overweight	25	0.57 (0.37, 0.75)	0.66 (0.49, 0.81)	0.84 (0.74, 0.92)	0.62 (0.44, 0.79)	0.89 (0.82, 0.95)	0.79 (0.65, 0.87)
Obese	10	0.78 (0.55, 0.93)	0.82 (0.61, 0.94)	0.92 (0.81, 0.98)	0.90 (0.76, 0.97)	0.94 (0.86, 0.98)	0.94 (0.85, 0.98)
Winter	12	0.71 (0.47, 0.89)	0.76 (0.54, 0.91)	0.90 (0.79, 0.97)	0.89 (0.77, 0.96)	0.89 (0.76, 0.96)	0.90 (0.78, 0.96)
Spring	19	0.58 (0.36, 0.78)	0.58 (0.36, 0.78)	0.94 (0.88, 0.97)	0.83 (0.71, 0.92)	0.98 (0.95, 0.99)	0.69 (0.49, 0.85)
Autumn	34	0.58 (0.41, 0.73)	0.65 (0.50, 0.78)	0.85 (0.77, 0.91)	0.68 (0.54, 0.81)	0.91 (0.85, 0.95)	0.80 (0.69, 0.88)
Overall[b]	65	0.85 (0.84, 0.86)	0.87 (0.86, 0.88)	0.94 (0.93, 0.95)	0.89 (0.88, 0.89)	0.95 (0.94, 0.96)	0.87 (0.86, 0.88)

LPA = light-intensity physical activity; MVPA = moderate-to-vigorous physical activity; SED = Sedentary time

[a] Adjusted for age, BMI, and season when the data were collected. Age (younger if age <50 years, older if age ≥50), BMI (normal weight if BMI<25.0, overweight if 25.0≥BMI<30.0, or obese if BMI≥30.0), and season of first data collection (winter, spring or autumn).

[b] Adjusted ICCs using a 14-day assessment period

Table 5: Intraclass Correlation (ICC) Values for Different Subsets Based on Missing Data.

Variables	All weeks[a]	Subset with no missing data[b]	Subset with week 1 and week 2 data	Subset with week 1 and week 3 data	Subset with week 1 and week 4 data
N	71	65	69	68	65
Time in bed (h/d)	0.42 (0.33, 0.52)	0.67 (0.61, 0.72)	0.64 (0.60, 0.67)	0.58 (0.54, 0.59)	0.80 (0.78, 0.82)
Total Sleep (h/d)	0.77 (0.72, 0.82)	0.72 (0.66, 0.76)	0.82 (0.80, 0.84)	0.64 (0.60, 0.67)	0.83 (0.82, 0.84)
SED (h/d)	0.84 (0.80, 0.87)	0.90 (0.88, 0.92)	0.81 (0.80, 0.82)	0.78 (0.75, 0.80)	0.89 (0.88, 0.90)
SED30min (min/d)	0.85 (0.81, 0.88)	0.81 (0.77, 0.84)	0.81 (0.79, 0.83)	0.69 (0.66, 0.72)	0.79 (0.77, 0.80)
LPA (min/d)	0.91 (0.89, 0.93)	0.92 (0.91, 0.93)	0.95 (0.94, 0.96)	0.92 (0.91, 0.93)	0.88 (0.87, 0.90)
MVPA (min/d)	0.97 (0.96, 0.97)	0.77 (0.72, 0.80)	0.76 (0.72, 0.83)	0.87 (0.85, 0.59)	0.78 (0.76, 0.80)

Notes: ICCs are adjusted for age, BMI, and season when the data were collected.

LPA = light-intensity physical activity; MVPA = moderate-to-vigorous physical activity; SED = Sedentary time

[a] Have data at week 1 and either week 2, week 3, week 4, or all of them.

[b] Have complete data at week 1, week 2, week 3 and week 4.

Table 6: Intraclass Correlation Values (ICC) excluding the first day of measurement

Variables	Model 1[a]	Model 2[b]	Model 3[c]	Model 4[d]
Time in bed (h/d)	0.67 (0.61, 0.72)	0.71 (0.66, 0.76)	0.85 (0.84, 0.86)	0.83 (0.81, 0.84)
Total Sleep (h/d)	0.72 (0.66, 0.76)	0.74 (0.70, 0.78)	0.87 (0.86, 0.88)	0.86 (0.85, 0.87)
SED (h/d)	0.90 (0.88, 0.92)	0.91 (0.89, 0.92)	0.94 (0.93, 0.95)	0.94 (0.93, 0.94)
SED30min (min/d)	0.81 (0.77, 0.84)	0.85 (0.82, 0.88)	0.89 (0.88, 0.89)	0.89 (0.88, 0.90)
LPA (min/d)	0.92 (0.91, 0.93)	0.92 (0.91, 0.94)	0.95 (0.95, 0.96)	0.95 (0.95, 0.96)
MVPA (min/d)	0.77 (0.72, 0.80)	0.74 (0.68, 0.77)	0.87 (0.86, 0.88)	0.85 (0.84, 0.86)

Notes: ICCs are adjusted for age, BMI, and season when the data were collected.

LPA = light-intensity physical activity; MVPA = moderate-to-vigorous physical activity; Period = two-week measurement period; SED = Sedentary time

[a] ICCs using 7-day assessment period.
[b] ICCs using 7-day assessment period and removing first day.
[c] ICCs using 14-day assessment period.
[d] ICCs using 14-day assessment period and removing first day.

Table 7. Cross-ranking matrix by tertiles at baseline and mean of weeks 2,3 and 4.

| Tertiles at baseline | Tertiles for mean of weeks 2, 3 and 4 | | | | |
	1	2	3	Total	Percent agreement
Sedentary time					
1	19	2	0	21	
2	2	17	3	22	
3	0	3	19	22	
Total	21	22	22	**65**	**84.61%**
LPA					
1	18	3	0	21	
2	3	17	2	22	
3	0	3	19	22	
Total	21	22	22	65	**83.08%**
MVPA					
1	16	4	1	21	
2	5	15	2	22	
3	0	4	18	22	
Total	21	22	22	65	**75.38%**
Sleep					
1	12	8	1	21	
2	9	10	3	22	
3	1	4	17	22	
Total	21	22	22	65	**60.00%**

Percent agreement values indicate classified in the same tertile at both-time points.

Sedentary time. Baseline: T1: <700.62 min; T2: 700.63 to <772.04 min; T3: ≥772.05 min. Time 2/3/4: T1: < 689.19 min; T2: 689.20 to < 769.57 min; T3: ≥769.58 min.

Light physical activity (LPA). Baseline: T1: <166.74 min; T2: 166.75 to < 229.82 min; T3: ≥ 229.83 min. Time 2/3/4: T1: < 153.60 min; T2: 153.61 to < 240.43 min; T3: ≥ 240.44 min.

Moderate to vigorous physical activity (MVPA). Baseline: T1: < 9.85 min; T2: 9.86 to <26.09 min; T3: ≥26.10 min. Time 2/3/4: T1: <10.02 min; T2: 10.03 to <24.40 min; T3: ≥24.41 min.

Sleep time. Baseline: Baseline: T1: <369.83 min; T2: 369.84 to <414.10 min; T3: ≥414.11 min. Time 2/3/4: T1: < 363.75 min; T2: 363.76 to <400.11 min; T3: ≥400.12 min.